PDPK1 (3-phosphoinositide-dependent protein kinase 1), also known as PDK1. is a serine/threonine kinase that plays a pivotal role in cell signaling pathways, particularly the PI3K/Akt (phosphatidylinositol 3-kinase/protein kinase B) cascade. It acts as a master regulator by phosphorylating and activating downstream AGC kinase family members, including Akt, PKC, and SGK, which are critical for cell survival, proliferation, and metabolism. Dysregulation of PDPK1 is implicated in various diseases, such as cancer, diabetes, and neurodegenerative disorders, making it a key therapeutic target.
Antibodies against PDPK1 are essential tools for studying its expression, localization, and activation in biological systems. They are widely used in techniques like Western blotting, immunoprecipitation, and immunohistochemistry to assess PDPK1 levels or phosphorylation status in disease models or drug response studies. These antibodies help identify PDPK1's role in oncogenic signaling, metabolic regulation, or resistance mechanisms. Both monoclonal and polyclonal PDPK1 antibodies are available, often validated for specificity using knockout cell lines or phospho-specific epitope recognition. Researchers also utilize them to explore PDPK1 interactions with other signaling molecules or evaluate its potential as a biomarker. The development of selective PDPK1 inhibitors in preclinical studies further underscores the importance of reliable antibodies for target validation and mechanistic research.